GlassScriptPhysician profile
Sean M Dougherty
NPI 1407089261
$1,127.44
in general payments reported to CMS, 2019-2025
24 companies · $354 in 2025
The $354 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $12.80 · 2023: $384 · 2024: $252 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.85 | 2023-2024 | Jardiance |
| Horizon Therapeutics Plc | $124.98 | 2019 | |
| Globus Medical, INC. | $122.15 | 2023 | Mini Fragment System |
| Medtronic, INC. | $89.92 | 2025 | Minimed 780g, Inceptiv |
| Glaxosmithkline, LLC. | $66.44 | 2023-2025 | Trelegy Ellipta, Nucala |
| Depuy Synthes Sales INC. | $55.20 | 2024 | Motoband, Motoband Cp, Minibunion |
| Bayer Healthcare Pharmaceuticals INC. | $54.87 | 2024-2025 | |
| Mimedx Group, INC. | $47.67 | 2025 | |
| Lilly USA, LLC | $44.81 | 2024-2025 | Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $43.41 | 2023-2025 | Takhzyro, Eohilia |
| Xeris Pharmaceuticals, INC. | $40.21 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $36.27 | 2024-2025 | |
| Averitas Pharma INC. | $27.16 | 2024 | Qutenza |
| Sanofi-Aventis U.S. LLC | $25.87 | 2024 | |
| Tactile Systems Technology INC | $25.52 | 2025 | Nimbl, Flexitouch Plus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $24.17 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $23.00 | 2023 | Dupixent |
| Kaleo, INC. | $22.10 | 2023 | Auvi-Q |
| Urgo Medical North America, LLC | $21.83 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Genzyme Corporation | $19.72 | 2023 | |
| Novo Nordisk INC | $17.97 | 2025 | Wegovy |
| Vertex Pharmaceuticals Incorporated | $17.95 | 2025 | |
| Abbott Laboratories | $17.57 | 2025 | Freestyle Libre 3 |
| Smith+Nephew, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.